Analysts Set Affimed (NASDAQ:AFMD) PT at $16.00

Affimed (NASDAQ:AFMD) has been given an average rating of “Moderate Buy” by the five brokerages that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $16.00.

AFMD has been the topic of a number of recent analyst reports. Stifel Nicolaus dropped their price objective on Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research note on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Affimed in a research report on Friday, November 15th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a research report on Tuesday, November 19th.

Affimed Stock Performance

Affimed stock opened at $2.62 on Friday. Affimed has a 52-week low of $2.61 and a 52-week high of $8.95. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.93 and a current ratio of 1.93. The firm has a 50 day moving average price of $3.38 and a two-hundred day moving average price of $4.42.

Affimed (NASDAQ:AFMD) last announced its earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09). The firm had revenue of $0.17 million for the quarter, compared to the consensus estimate of $1.67 million. Affimed had a negative return on equity of 193.84% and a negative net margin of 7,836.26%. As a group, equities research analysts forecast that Affimed will post -4 EPS for the current year.

Institutional Trading of Affimed

Hedge funds have recently bought and sold shares of the business. FMR LLC raised its holdings in Affimed by 30.0% during the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 4,086 shares during the last quarter. Choreo LLC bought a new stake in shares of Affimed during the second quarter worth about $54,000. Intellectus Partners LLC raised its holdings in shares of Affimed by 12.2% in the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after acquiring an additional 10,250 shares during the last quarter. Jane Street Group LLC bought a new position in Affimed in the 3rd quarter valued at about $44,000. Finally, Point72 Asset Management L.P. boosted its stake in Affimed by 4.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after purchasing an additional 15,108 shares during the last quarter. Institutional investors and hedge funds own 30.82% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.